Ps1208 Effects of NKTR-255, a Polymer Conjugated Human Il-15, on Efficacy of Cd19 Car T Cell Immunotherapy in a Preclinical Lymphoma Model

Chou, Chiang-Ting; Fräßle, Simon P.; Hawkins, Reed M.; Steinmetz, Rachel N.; Phi, Tinh-Doan; Busch, Dirk H.; Miyazaki, Takahiro; Marcondes, Mario Q.; Riddell, Stanley R.; Turtle, Cameron J.

doi:10.1097/01.hs9.0000563116.66927.0a

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CAR-NK candidate NK-92MI showed enhanced cytotoxicity in vitro against CD138 + MM cell lines and primary MM cells as compared to empty vector controls [ 51 ]. A different candidate CAR-NK cellular therapy, NKTR-255, was shown to improve antitumor efficacy and kinetics when given in combination with CD19 CAR T cells [ 52 ]. Another in vitro study of CAR-NK cells targeting SLAMF7 cell therapy demonstrated an enhanced interferon-gamma production and cytotoxic activity against primary MM tumor cells, as well as inhibition of MM tumor growth in a xenograft mouse model [ 53 ].…”

Section: Cellular Therapymentioning

confidence: 99%

Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies

Stalker

Mark

2022

Current Oncology

View full text Add to dashboard Cite

Major progress has been made in the upfront treatment of multiple myeloma, but the disease ultimately relapses and leads to death in the vast majority of those afflicted. New treatment strategies and modalities are necessary to treat myeloma in relapse, particularly in cases of triple-refractory status defined by disease progression during or shortly after treatment with immunomodulatory agents, proteasome inhibitors, and anti-CD38 monoclonal antibody therapy. In this manuscript, we review recent promising developments in the treatment of triple-class refractory myeloma including bispecific antibodies and T cell engagers, chimeric antigen receptor cellular therapies, as well as chemotherapeutics with novel mechanisms of action.

show abstract

Section: Cellular Therapymentioning

confidence: 99%